The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
